摘要
Colorectal cancer (CRC) is the third most common malignant tumor worldwide and the fourth major cause of cancer-related death, with high morbidity and increased mortality year by year. Although significant progress has been made in the therapy strategies for CRC, the great difficulty in early diagnosis, feeble susceptibility to radiotherapy and chemotherapy, and high recurrence rates have reduced therapeutic efficacy resulting in poor prognosis. Therefore, it is urgent to understand the pathogenesis of CRC and unravel novel biomarkers to improve the early diagnosis, treatment and prediction of CRC recurrence. Long non-coding RNAs (lncRNAs) are non-coding RNAs with a length of more than 200 nucleotides, which are abnormally expressed in tumor tissues and cell lines, activating or inhibiting specific genes through multiple mechanisms including transcription and translation. A growing number of studies have shown that lncRNAs are important regulators of microRNAs (miRNAs, miRs) expression in CRC and may be promising biomarkers and potential therapeutic targets in the research field of CRC. This review mainly summarizes the potential application value of lncRNAs as novel biomarkers in CRC diagnosis, radiotherapy, chemotherapy and prognosis. Additionally, the significance of lncRNA SNHGs family and lncRNA-miRNA networks in regulating the occurrence and development of CRC is mentioned, aiming to provide some insights for understanding the pathogenesis of CRC and developing new diagnostic and therapeutic strategies.
学科与关键词
- LncRNAs, the Molecules Involved in Communications With Colorectal Cancer Stem CellsFan, Boyang; Zhang, Qian; Wang, Ning*; Wang, Guiyu*Frontiers in Oncology, 2022, 12: 811374.被引 4
- Long non-coding RNA: a new player in cancerZhang Hua; Chen Zhenhua; Wang Xinxin; Huang Zunnan; He Zhiwei*; Chen YueqinJournal of Hematology and Oncology, 2013, 6: 37.被引 58
- An integrative transcriptome analysis reveals potential predictive, prognostic biomarkers and therapeutic targets in colorectal cancerSamadi, Pouria; Soleimani, Meysam; Nouri, Fatemeh; Rahbarizadeh, Fatemeh; Najafi, Rezvan; Jalali, Akram*BMC CANCER, 2022, 22(1): 835.被引 20
